ArriVent BioPharma Inc AVBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 47.3% Share Drop
-
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
-
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
-
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
-
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
Trading Information
- Previous Close Price
- $19.20
- Day Range
- $18.18–21.23
- 52-Week Range
- $11.36–35.83
- Bid/Ask
- $17.60 / $22.00
- Shares Outstanding
- 49.31M
- Market Cap
- $1.04B
- Volume/Avg
- 3M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 77
- Website
- https://www.arrivent.com
Valuation
|
Metric
|
AVBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.77 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVBP
|
|---|---|
Quick Ratio | 13.40 |
Current Ratio | 14.16 |
Interest Coverage | — |
Quick Ratio
AVBP
Profitability
|
Metric
|
AVBP
|
|---|---|
Return on Assets (Normalized) | −43.22% |
Return on Equity (Normalized) | −46.57% |
Return on Invested Capital (Normalized) | −50.47% |
Return on Assets
AVBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|RYdgmC# | LOCK|yg<@z | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|gzlyw@^ | LOCK|qB<M | $83B | |||
| Moderna Inc
MRNA
| LOCK|$!y@v< | LOCK|^^ | $80B | |||
| argenx SE ADR
ARGX
| LOCK|$lb$@Q | LOCK|xt | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@>nC&V& | LOCK|<K | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<<b?@$ | LOCK|nWL&X | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G%?XL&$s | LOCK|X!Z& | $28B | |||
| Incyte Corp
INCY
| LOCK|?Xd^Sf | LOCK|zjJ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|j<Jjh% | LOCK|NQ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|bxRxwS | LOCK|g$ | $14B |
United States